Verition Fund Management
NRIX icon

Verition Fund Management’s Nurix Therapeutics NRIX Stock Holding History

Verition Fund Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-68,754
Closed -$1.3M – 3144
2025
Q4 		$1.3M Buy
+68,754
New +$988K 0.01% 1948
2025
Q3 		– Sell
-41,922
Closed -$477K – 3931
2025
Q2 		$477K Buy
+41,922
New +$453K ﹤0.01% 2968
2025
Q1 		– Sell
-31,396
Closed -$592K – 3590
2024
Q4 		$592K Buy
+31,396
New +$720K ﹤0.01% 2374
2024
Q2 		– Sell
-13,175
Closed -$194K – 3179
2024
Q1 		$194K Buy
+13,175
New +$142K ﹤0.01% 2506

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Verition Fund Management's NRIX Position: Q1 2026 in Review

Verition Fund Management sold out of Nurix Therapeutics (NRIX) in Q1 2026, closing a stake of 68,754 shares — an estimated $1.3M sold.

Verition Fund Management first reported a position in NRIX in Q1 2024 and held it in 4 quarters. The position peaked at $1.3M in Q4 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Verition Fund Management reported no remaining Nurix Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 68,754 Nurix Therapeutics shares in Q1 2026, an estimated $1.3M.
  • Verition Fund Management first reported a position in Nurix Therapeutics in Q1 2024 and held it in 4 quarters.
  • Verition Fund Management's Nurix Therapeutics position peaked at $1.3M in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.